Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex in the EU,[3]Imvamune in Canada,[2] and Jynneos in the US[1]) against smallpox and mpox,[4] having fewer side effects than smallpox vaccines derived from other poxviruses.[5]
This third-generation smallpox vaccine has the advantage that it cannot reproduce complete virions in human cells, "the block of the MVA life cycle occurs at the step of virion assembly resulting in assembly of immature virus particles that are not released from the infected cell."[5]
By inserting antigen genes into its genome, modified vaccinia Ankara virus is also used as an experimental viral vector for vaccines against non-poxvirus diseases.[6]
^ abc"Jynneos- vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen injection, suspension". DailyMed. 14 February 2022. Archived from the original on 27 May 2022. Retrieved 26 May 2022.
^ ab"Product Monograph including Patient Medication Information - Imvamune" (PDF). 26 November 2021. Archived (PDF) from the original on 26 May 2022. Retrieved 19 June 2022.
^ ab"Imvanex EPAR". European Medicines Agency (EMA). Archived from the original on 27 April 2022. Retrieved 2 October 2014.
^"NACI Rapid Response - Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada" (PDF). Public Health Agency of Canada. June 2022. Archived (PDF) from the original on 19 June 2022. Retrieved 19 June 2022.
^ abCite error: The named reference Volz was invoked but never defined (see the help page).
^Cite error: The named reference :0 was invoked but never defined (see the help page).
and 24 Related for: Modified vaccinia Ankara information
ModifiedvacciniaAnkara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex...
original on 24 May 2022. Retrieved 26 May 2022. "Jynneos- vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen injection, suspension"...
strains below). A smallpox vaccine, Imvanex, which is based on the ModifiedvacciniaAnkara strain, was approved by the European Medicines Agency (EMA) in...
including replication-competent and replication-deficient strains. Modifiedvacciniaankara (MVA) is a replication-deficient strain that has been safely used...
MVA85A (modifiedvacciniaAnkara 85A) is a vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It...
derived from the ModifiedvacciniaAnkara virus. MVA-BN is characterized by the inability to replicate in human cells, contrary to other vaccinia-based vaccines...
Analysis, an immunoprofiling technology Mitral valve area ModifiedvacciniaAnkara, a virus modified to carry vaccines Microsoft Virtual Academy, a free online...
company which develops vaccines. GeoVax's development platform uses ModifiedVacciniaAnkara (MVA) vector technology, with improvements to antigen design and...
variant glycoprotein, while the second component MVA-BN is the ModifiedVaccinia Virus Ankara – Bavarian Nordic (MVA-BN) Filo-vector. This product commenced...
patients. This vaccine is built on a FDA-approved platform known as modifiedvacciniaankara, also known as MVA. This platform has famously been used safely...
producing vaccinia strains. The ModifiedvacciniaAnkara strain in this regard has much gene loss related to in vitro passage, and horsepox being a vaccinia strain...
Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice". Brazilian...
IgD, and IgE) previously have been researched for use with ModifiedVaccinia virus Ankara, more so than VIGIV as a treatment for monkeypox. Cangene Eczema...
allergies. The first use of a viral vector for vaccination – a ModifiedVacciniaAnkara Virus expressing HBsAg – was published by Bernard Moss and colleagues...
to fund a vaccine against MERS-CoV (only) using a recombinant modifiedvacciniaAnkara viral vector technology. In September 2018, US$19 million to Janssen...
non-infectious HIV-like particles and boosting with a recombinant modifiedvacciniaAnkara virus also expressing non-infectious HIV-like particles. The vaccine...
mesothelioma), immunoglobulin E, and vaccine design of recombinant ModifiedVacciniaAnkara virus (MVA) or Fowlpoxvirus. Siccardi developed a recombinant MVA-based...
transmembrane domain from shark invariant chain. And the latter, a ModifiedVacciniaAnkara (MVA) vector encoding the LS2 fused to the C-terminal end of the...
function and immunological effects of the HI virus (HIV) and the ModifiedVacciniaAnkara Virus (MVA), including in particular the Nef protein of HIV and...
vaccines. As of 2021 GeoVax was developing MVA-SUDV-VLP, which is a modifiedvacciniaAnkara virus producing Sudan virus-like particles; early data from their...
Sequential Immunization with gp140 Boosts Immune Responses Primed by ModifiedVacciniaAnkara or DNA in HIV-Uninfected South African Participants. PLoS One....
"Optimising T cell (Re)boosting strategies for adenoviral and modifiedvacciniaAnkara vaccine regimens in humans". npj Vaccines. 5: 94. doi:10.1038/s41541-020-00240-0...
protective efficacy of malaria DNA vaccination by boosting with modifiedvaccinia virus Ankara". Nature Medicine. 4 (4): 397–402. doi:10.1038/NM0498-397. ISSN 1078-8956...
1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, ModifiedVacciniaAnkara-HIV-1 B./C Candidate Vaccine. PLoS One. 2010 Jan 25;5(1):e8816...
Global Information